“Hot Cross Bun” Sign in a Patient With Kelch-like Protein 11 Rhombencephalitis

Masoud Majed; Ajay A. Madhavan; Sean J. Pittock; Divyanshu Dubey

doi:10.1016/j.mayocp.2021.11.024

“Hot Cross Bun” Sign in a Patient With Kelch-like Protein 11 Rhombencephalitis

Masoud Majed, Ajay A. Madhavan, Sean J. Pittock, Divyanshu Dubey

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	122-123
Number of pages	2
Journal	Mayo Clinic proceedings
Volume	97
Issue number	1
DOIs	https://doi.org/10.1016/j.mayocp.2021.11.024
State	Published - Jan 2022

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/j.mayocp.2021.11.024

Cite this

@article{f435b13de242433086c4319147762a30,

title = "“Hot Cross Bun” Sign in a Patient With Kelch-like Protein 11 Rhombencephalitis",

author = "Masoud Majed and Madhavan, {Ajay A.} and Pittock, {Sean J.} and Divyanshu Dubey",

note = "Funding Information: Potential Competing Interests: Dr Dubey has consulted for UCB, Immunovant, and Astellas Pharmaceuticals. All compensation for consulting activities is paid directly to Mayo Clinic. He has patents pending for KLHL11 and LUZP4 as markers of neurological autoimmunity. Dr Pittock has received grants from Alexion, National Institutes of Health, MedImmune/Viela Bio, Grifols, and Guthy Jackson; all compensation paid directly to Mayo Clinic. He has received consulting fees from Alexion, MedImmune/Viela Bio, and Euroimmun; all compensation paid directly to Mayo Clinic. He has also received consulting fees from Roche/Genentech, Sage Therapeutics, Prime Therapeutics, UCB, and Astellas; all compensation paid directly to Mayo Clinic and as personal compensation. He owns Patent #8,889,102 and Patent #9,891,219B2. He has patents pending for GFAP-IgG, Septin-5-IgG, MAP1B-IgG, Kelch-like protein 11, and PDE10A. Dr Pittock has received personal compensation to attend the UCB Advisory Board Meeting in Stockholm, Sweden, on September 10, 2019. Dr Pittock received personal compensation/honorarium to attend the NMOSD Biomarker Advisory Board Meeting in Munich, Germany, on November 8, 2019. All travel expenses were paid by Hoffman/LaRoche AG. He has received personal compensation as an Advisory Board Member and as a member of the Roche SAkuraBONSAI Steering Committee. He has received an honorarium and travel expenses to attend the NMOSD Advisory Board Meeting on March 8 to 10, 2019. All travel expenses were paid by Alexion. Honorarium was paid directly to the Mayo Clinic. He received no personal compensation. Dr Pittock has received an honorarium and travel expenses to attend the NMOSD Advisory Board Meeting on June 1, 2019. All travel expenses were paid by Alexion. Honorarium was paid directly to the Mayo Clinic. He received no personal compensation. Dr Pittock received personal compensation to attend the virtual Genentech NMOSD Advisory Board Meeting on October 1, 2020. The other authors report no competing interests.",

year = "2022",

month = jan,

doi = "10.1016/j.mayocp.2021.11.024",

language = "English (US)",

volume = "97",

pages = "122--123",

journal = "Mayo Clinic proceedings",

issn = "0025-6196",

publisher = "Elsevier Science",

number = "1",

}

TY - JOUR

T1 - “Hot Cross Bun” Sign in a Patient With Kelch-like Protein 11 Rhombencephalitis

AU - Majed, Masoud

AU - Madhavan, Ajay A.

AU - Pittock, Sean J.

AU - Dubey, Divyanshu

N1 - Funding Information: Potential Competing Interests: Dr Dubey has consulted for UCB, Immunovant, and Astellas Pharmaceuticals. All compensation for consulting activities is paid directly to Mayo Clinic. He has patents pending for KLHL11 and LUZP4 as markers of neurological autoimmunity. Dr Pittock has received grants from Alexion, National Institutes of Health, MedImmune/Viela Bio, Grifols, and Guthy Jackson; all compensation paid directly to Mayo Clinic. He has received consulting fees from Alexion, MedImmune/Viela Bio, and Euroimmun; all compensation paid directly to Mayo Clinic. He has also received consulting fees from Roche/Genentech, Sage Therapeutics, Prime Therapeutics, UCB, and Astellas; all compensation paid directly to Mayo Clinic and as personal compensation. He owns Patent #8,889,102 and Patent #9,891,219B2. He has patents pending for GFAP-IgG, Septin-5-IgG, MAP1B-IgG, Kelch-like protein 11, and PDE10A. Dr Pittock has received personal compensation to attend the UCB Advisory Board Meeting in Stockholm, Sweden, on September 10, 2019. Dr Pittock received personal compensation/honorarium to attend the NMOSD Biomarker Advisory Board Meeting in Munich, Germany, on November 8, 2019. All travel expenses were paid by Hoffman/LaRoche AG. He has received personal compensation as an Advisory Board Member and as a member of the Roche SAkuraBONSAI Steering Committee. He has received an honorarium and travel expenses to attend the NMOSD Advisory Board Meeting on March 8 to 10, 2019. All travel expenses were paid by Alexion. Honorarium was paid directly to the Mayo Clinic. He received no personal compensation. Dr Pittock has received an honorarium and travel expenses to attend the NMOSD Advisory Board Meeting on June 1, 2019. All travel expenses were paid by Alexion. Honorarium was paid directly to the Mayo Clinic. He received no personal compensation. Dr Pittock received personal compensation to attend the virtual Genentech NMOSD Advisory Board Meeting on October 1, 2020. The other authors report no competing interests.

PY - 2022/1

Y1 - 2022/1

UR - http://www.scopus.com/inward/record.url?scp=85121600684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121600684&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2021.11.024

DO - 10.1016/j.mayocp.2021.11.024

M3 - Comment/debate

C2 - 34996544

AN - SCOPUS:85121600684

SN - 0025-6196

VL - 97

SP - 122

EP - 123

JO - Mayo Clinic proceedings

JF - Mayo Clinic proceedings

IS - 1

ER -

“Hot Cross Bun” Sign in a Patient With Kelch-like Protein 11 Rhombencephalitis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this